T.Man Pharmaceutical PCL (BKK:TMAN)

Market Cap	4.32B -27.0%
Revenue (ttm)	2.38B +8.2%
Net Income	449.38M +3.7%
EPS	1.13 -17.1%
Shares Out	400.00M
PE Ratio	9.54
Forward PE	8.64
Dividend	0.20 (1.85%)
Ex-Dividend Date	Aug 26, 2025

Volume	311,931
Average Volume	135,623
Open	10.70
Previous Close	10.60
Day's Range	10.50 - 10.90
52-Week Range	9.90 - 13.80
Beta	n/a
RSI	56.52
Earnings Date	Feb 25, 2026

About T.Man Pharmaceutical PCL

T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties’ Brand, and Trading Products. It offers antibacterial, central nervous system, corticosteroid, chronic diseases, gastrointestinal, respiratory, and musculoskeletal drugs, as well as medical devices, vaginal suppositories, dermatological, mouth, and throat products. The company also provides herbal and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 944
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: TMAN

Financial Performance

In 2024, T.Man Pharmaceutical PCL's revenue was 2.23 billion, an increase of 12.42% compared to the previous year's 1.98 billion. Earnings were 450.70 million, an increase of 4.55%.